KBC Group
PCVX icon

KBC Group’s Vaxcyte PCVX Stock Holding History

KBC Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$222K Hold
3,898
– – ﹤0.01% 981
2026
Q2 		$227K Hold
3,898
– – ﹤0.01% 997
2026
Q1 		$227K Hold
3,898
– – ﹤0.01% 937
2025
Q4 		$180K Hold
3,898
– – ﹤0.01% 959
2025
Q3 		$140K Hold
3,898
– – ﹤0.01% 1074
2025
Q2 		$127K Sell
3,898
-884
-18% -$29K ﹤0.01% 1068
2025
Q1 		$181K Buy
4,782
+7
+0.1% +$560 ﹤0.01% 1140
2024
Q4 		$391K Buy
4,775
+2,092
+78% +$208K ﹤0.01% 858
2024
Q3 		$307K Buy
2,683
+322
+14% +$29K ﹤0.01% 790
2024
Q2 		$178K Buy
2,361
+351
+17% +$23.9K ﹤0.01% 904
2024
Q1 		$137K Buy
2,010
+472
+31% +$32.7K ﹤0.01% 986
2023
Q4 		$97K Hold
1,538
– – ﹤0.01% 1080
2023
Q3 		$78K Buy
+1,538
New +$75.9K ﹤0.01% 1123

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Pivotal bioVenture Partners Investment Advisor
Pivotal bioVenture Partners Investment Advisor San Francisco, California $252M AUM 45.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

KBC Group's PCVX Position: Q3 2026 in Review

KBC Group held its Vaxcyte (PCVX) position steady in Q3 2026 at 3,898 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #981.

KBC Group first reported a position in PCVX in Q3 2023 and has held it in 13 quarters since. The position peaked at $391K in Q4 2024. 259 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.

  • KBC Group held 3,898 shares of Vaxcyte worth $222K as of Q3 2026.
  • KBC Group left its Vaxcyte share count unchanged in Q3 2026.
  • Vaxcyte made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #981 holding.
  • KBC Group first reported a position in Vaxcyte in Q3 2023 and has held it in 13 quarters since.
  • KBC Group's Vaxcyte position peaked at $391K in Q4 2024.
  • 259 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.